Everolimus: A proliferation signal inhibitor with clinical applications in organ transplantation, oncology, and cardiology

Pharmacotherapy

Volumn 30, Issue 10, 2010, Pages 1044-1056

  Gabardi, Steven ^a   Baroletti, Steven A ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b METROWEST MEDICAL CENTER   (United States)

Author keywords

Drug eluting stent; Everolimus; Heart transplant; Immunosuppressant; Mammalian target of rapamycin; mTOR inhibitor; Percutaneous coronary intervention; Renal cell carcinoma; Renal transplant; Solid organ transplant

Indexed keywords

ATORVASTATIN; AZATHIOPRINE; AZITHROMYCIN; BASILIXIMAB; CALCINEURIN INHIBITOR; CHOLESTEROL; CORTICOSTEROID; CREATININE; CYCLOSPORIN; ERYTHROMYCIN; EVEROLIMUS; ITRACONAZOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PRAVASTATIN; PREDNISOLONE; RAPAMYCIN; RIFAMPICIN; SORAFENIB; SUNITINIB; TACROLIMUS; TRIACYLGLYCEROL;

ABDOMINAL PAIN; ACNE; ACUTE GRAFT REJECTION; ADVANCED CANCER; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ASTHENIA; BACTERIAL INFECTION; BONE MARROW SUPPRESSION; CARDIAC GRAFT REJECTION; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONSTIPATION; COUGHING; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ELUTING STENT; DRUG HALF LIFE; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; DYSPNEA; EPISTAXIS; FOOD AND DRUG ADMINISTRATION; GRAFT REJECTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERKALEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; HYPOCALCEMIA; HYPOPHOSPHATEMIA; INSOMNIA; KIDNEY CARCINOMA; KIDNEY DYSFUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; LIMB PAIN; LIVER FUNCTION TEST; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; MICROANGIOPATHY; MOUTH ULCER; MUCOSA INFLAMMATION; MYCOSIS; NAUSEA; NEPHROTOXICITY; OPPORTUNISTIC INFECTION; ORGAN TRANSPLANTATION; PARESTHESIA; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PNEUMONIA; PROTEINURIA; PRURITUS; RASH; RECIPIENT; RESTENOSIS; REVIEW; SIDE EFFECT; STOMATITIS; TASTE DISORDER; THORAX PAIN; THROMBOCYTOPENIA; TRIACYLGLYCEROL BLOOD LEVEL; VOMITING; WEIGHT REDUCTION; WOUND HEALING IMPAIRMENT; XEROSTOMIA;

DRUG INTERACTIONS; DRUG MONITORING; DRUG-ELUTING STENTS; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; NEOPLASMS; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 77957659746     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.30.10.1044     Document Type: Review

References (59)

1. Sarbassov DD, Ali SM, Sabatini DM. Growing roles for the mTOR pathway. Curr Opin Cell Biol 2005;17:596-603.
2. Hudes GR. Targeting mTOR in renal cell carcinoma. Cancer 2009;115:2313-20.
3. Kukreja N, Onuma Y, Serruys PW. Xience V everolimuseluting coronary stent. Expert Rev Med Devices 2009;6:219-29.
4. Butt M, Connolly D, Lip GY. Drug-eluting stents: a comprehensive appraisal. Future Cardiol 2009;5:141-57.
5. Schuler W, Sedrani R, Cottens S, et al. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 1997;64:36-42. (Pubitemid 27327197)
6. Dunn C, Croom KF. Everolimus: a review of its use in renal and cardiac transplantation. Drugs 2006;66:547-70.
7. Delgado JF, Manito N, Segovia J, et al. The use of proliferation signal inhibitors in the prevention and treatment of allograft vasculopathy in heart transplantation. Transplant Rev (Orlando) 2009;23:69-79.
8. Chapman JR, O'Connell PJ, Nankivell BJ. Chronic renal allograft dysfunction. J Am Soc Nephrol 2005;16:3015-26.
9. Oudard S, Medioni J, Aylllon J, et al. Everolimus (RAD001): an mTOR inhibitor for the treatment of metastatic renal cell carcinoma. Expert Rev Anticancer Ther 2009;9:705-17.
10. Sedrani R, Cottens S, Kallen J, Schuler W. Chemical modification of rapamycin: the discovery of SDZ RAD. Transplant Proc 1998;30:2192-4. (Pubitemid 28399473)
11. Kirchner GI, Meier-Wiedenbach I, Manns MP. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet 2004;43:83-95.
12. Mahalati K, Kahan BD. Clinical pharmacokinetics of sirolimus. Clin Pharmacokinet 2001;40:573-85.
13. Kovarik JM, Kahan BD, Kaplan B, et al. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first posttransplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine. Clin Pharmacol Ther 2001;69:48-56.
14. Neumayer HH, Paradis K, Korn A, et al. Entry-into-human study with the novel immunosuppressant SDZ RAD in stable renal transplant recipients. Br J Clin Pharmacol 1999;48: 694-703.
15. Budde K, Neumayer HH, Lehne G, et al. Tolerability and steady-state pharmacokinetics of everolimus in maintenance renal transplant patients. Nephrol Dial Transplant 2004;19: 2606-14.
16. Levy GA, Grant D, Paradis K, Campestrini J, Smith T, Kovarik JM. Pharmacokinetics and tolerability of 40-0-[2-hydroxyethyl]rapamycin in de novo liver transplant recipients. Transplantation 2001;71:160-3. (Pubitemid 32105797)
17. Kovarik JM, Hartmann S, Figueiredo J, et al. Effect of food on everolimus absorption: quantification in healthy subjects and a confirmatory screening in patients with renal transplants. Pharmacotherapy 2002;22:154-9.
18. Novartis Pharmaceuticals. Afinitor [everolimus] package insert. East Hanover, NJ; 2009.
19. Kirchner G, Mueller L, Winkler M, et al. Long-term pharmacokinetics of the metabolites of everolimus and cyclosporine in renal transplant recipients. Transplant Proc 2002;34:2233-4.
20. Kovarik JM, Sabia HD, Figueiredo J, et al. Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment. Clin Pharmacol Ther 2001;70:425-30.
21. Motzer RJ, Escudier B, Oudard S, et al, for the RECORD-1 Study Group. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449-56.
22. Kniepeiss D, Renner W, Trummer O, et al. The role of CYP3A5 genotypes in dose requirements of tacrolimus and everolimus after heart transplantation [published online ahead of print December 22, 2009]. Clin Transplant. Available from http://dx.doi.org/10.1111/j.1399-0012.2009.01198.x.
23. Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiactransplant recipients. N Engl J Med 2003;349:847-58. (Pubitemid 37025404)
24. Vigano M, Tuzcu M, Benza R, et al. Prevention of acute rejection and allograft vasculopathy by everolimus in cardiac transplants recipients: a 24-month analysis. J Heart Lung Transplant 2007;26:584-92. (Pubitemid 46818043)
25. Lehmkuhl HB, Arizon J, Vigano M, et al. Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients. Transplantation 2009;88:115-22.
26. Vitko S, Margreiter R, Weimar W, et al, for the RAD B201 Study Group. Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2005;5:2521-30.
27. Lorber MI, Mulgaonkar S, Butt KM, et al, for the B251 Study Group. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study. Transplantation 2005;80:244-52. (Pubitemid 41061682)
28. Lorber MI, Ponticelli C, Whelchel J, et al. Therapeutic drug monitoring for everolimus in kidney transplantation using 12-month exposure, efficacy, and safety data. Clin Transplant 2005;19:145-52. (Pubitemid 40424882)
29. Nashan B, Curtis J, Ponticelli C, Mourad G, Jaffe J, Haas T, for the B156 Study Group. Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label study. Transplantation 2004;78:1332-40.
30. Agha IA, Rueda J, Alvarez A, et al. Short course induction immunosuppression with thymoglobulin for renal transplant recipients. Transplantation 2002;73:473-5.
31. Vitko S, Tedesco H, Eris J, et al. Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies. Am J Transplant 2004;4:626-35.
32. Levy G, Schmidli H, Punch J, et al. Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results. Liver Transpl 2006;12:1640-8. (Pubitemid 44742543)
33. Gomez-Camarero J, Salcedo M, Rincon D, et al. Use of everolimus as a rescue immunosuppressive therapy in liver transplant patients with neoplasms. Transplantation 2007;84: 786-91. (Pubitemid 47480665)
34. De Simone P, Carrai P, Precisi A, et al. Conversion to everolimus monotherapy in maintenance liver transplantation: feasibility, safety, and impact on renal function. Transpl Int 2009;22:279-86.
35. Snell GI, Valentine VG, Vitulo P, et al. Everolimus versus azathioprine in maintenance lung transplant recipients: an international, randomized, double-blind clinical trial. Am J Transplant 2006;6:169-77.
36. Jac J, Giessinger M, Khan M, Willis J, Chiang S, Amato R. A phase II trial of RAD001 in patients with metastatic renal cell carcinoma [abstract]. J Clin Oncol 2007;25(June 20 suppl): abstract 5107.
37. Tanaka C, O'Reilly T, Kovarik JM, et al. Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. J Clin Oncol 2008;26: 1596-602.
38. Stone GW, Midei M, Newman W, et al. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA 2008;299:1903-13.
39. Serruys P, Ruygrok, P, Neuzner J, et al. A randomized comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: the SPIRIT II trial. EuroIntervention 2006;2:286-94.
40. Stone GW, Midei M, Newman W, et al. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the clinical evaluation of the Xience V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions (SPIRIT) III trial. Circulation 2009;119:680-6.
41. Lemos PA, Serruys PW, van Domburg RT, et al. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the "real world": the rapamycin-eluting stent evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation 2004;109:190-5.
42. Ong AT, Serruys PW, Aoki J, et al. The unrestricted use of paclitaxel- versus sirolimus-eluting stents for coronary artery disease in an unselected population: one-year results of the Taxus-stent evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registry. J Am Coll Cardiol 2005;45:1135-41. (Pubitemid 40432449)
43. Onuma Y, Kukreja N, Piazza N, et al. The everolimus-eluting stent in real-world patients: 6-month follow-up of the X-SEARCH (Xience V stent evaluated at Rotterdam Cardiac Hospital) registry. J Am Coll Cardiol 2009;54:269-76.
44. Albano L, Berthoux F, Moal MC, et al. Incidence of delayed graft function and wound healing complications after deceased-donor kidney transplantation is not affected by de novo everolimus. Transplantation 2009;88:69-76.
45. Anonymous. Cytomegalovirus. Am J Transplant 2004;4(suppl 10):51-8.
46. Kovarik JM, Beyer D, Schmouder RL. Everolimus drug interactions: application of a classification system for clinical decision making. Biopharm Drug Dispos 2006;27:421-6. (Pubitemid 46062146)
47. Kovarik JM, Kalbag J, Figueiredo J, Rouilly M, Frazier OL, Rordorf C. Differential influence of two cyclosporine formulations on everolimus pharmacokinetics: a clinically relevant pharmacokinetic interaction. J Clin Pharmacol 2002;42:95-9. (Pubitemid 34038374)
48. Novartis Pharmaceuticals. Zortress [everolimus] package insert. East Hanover, NJ; 2010.
49. Pascual J, Del Castillo D, Cabello M, et al. Interaction between everolimus and tacrolimus in renal transplant recipients: a pharmacokinetic controlled trial. Transplantation 2010;89:994-1000.
50. Kovarik JM, Beyer D, Bizot MN, Jiang Q, Shenouda M, Schmouder RL. Blood concentrations of everolimus are markedly increased by ketoconazole. J Clin Pharmacol 2005;45:514-18.
51. Kovarik JM, Hartmann S, Figueiredo J, Rouilly M, Port A, Rordorf C. Effect of rifampin on apparent clearance of everolimus. Ann Pharmacother 2002;36:981-5.
52. Kovarik JM, Hartmann S, Hubert M, et al. Pharmacokinetic and pharmacodynamic assessments of HMG-CoA reductase inhibitors when coadministered with everolimus. J Clin Pharmacol 2002;42:222-8.
53. Van Damme-Lombaerts R, Webb NA, Hoyer PF, et al. Singledose pharmacokinetics and tolerability of everolimus in stable pediatric renal transplant patients. Pediatr Transplant 2002;6: 147-52.
54. Hoyer PF, Ettenger R, Kovarik JM, et al. Everolimus in pediatric de nova renal transplant patients. Transplantation 2003;75:2082-5. (Pubitemid 36793297)
55. Pape L, Ahlenstiel T, Ehrich JH, Offner G. Reversal of loss of glomerular filtration rate in children with transplant nephropathy after switch to everolimus and low-dose cyclosporine A. Pediatr Transplant 2007;11:291-5. (Pubitemid 46570146)
56. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: kidney cancer, 2009. Available from www.nccn.org/professionals/ physicians-gls/PDF/kidney.pdf. Accessed August 31, 2009.
57. Starling RC, Hare JM, Hauptman P, et al. Therapeutic drug monitoring for everolimus in heart transplant recipients based on exposure-effect modeling. Am J Transplant 2004;4:2126-31.
58. Sheiban I, Villata G, Bollati M, Sillano D, Lotrionte M, Biondi-Zoccai G. Next-generation drug-eluting stents in coronary artery disease: focus on everolimus-eluting stent (Xience V). Vasc Health Risk Manag 2008;4:31-8.
59. Dailly E, Deslandes G, Hourmant M, et al. Comparison between a liquid chromatography-tandem mass spectrometry assay and a fluorescent polarization immunoassay to measure whole blood everolimus concentration in heart and renal transplantations. J Clin Lab Anal 2008;22:282-5.